ALK -Positive Histiocytosis —A Distinct Histiocytic Entity Deserving Recognition

To the Editor It is with great interest that we read the recent article by Xu et al that described 2 infants with systemic histiocytic neoplasms harboring ALK translocations who were successfully treated with the ALK inhibitor alectinib. To our surprise, the authors classified the disease as systemic juvenile xanthogranuloma (JXG) without any mention of ALK-positive histiocytosis and stated that the treatment method had not been previously reported.
Source: JAMA Dermatology - Category: Dermatology Source Type: research